Literature DB >> 11512081

Bartonellosis (Carrión's disease) in the modern era.

C Maguina1, P J Garcia, E Gotuzzo, L Cordero, D H Spach.   

Abstract

Bartonellosis remains a major problem in Peru, but many contemporary aspects of this disease have not been adequately described. We examined the cases of 145 symptomatic patients in Lima, Peru, in whom bartonellosis was diagnosed from 1969 through 1992, including 68 patients in the acute (hematic) phase and 77 patients in the eruptive (verruga) phase. In modern Peru, symptomatic patients who have acute-phase bartonellosis typically present with a febrile illness and systemic symptoms caused by profound anemia; most patients respond successfully to treatment with chloramphenicol. Patients who have eruptive-phase bartonellosis most often present with cutaneous verrugas but may have less specific symptoms, such as fever and arthralgias; diagnosis can be confirmed in such patients by Western immunoblotting, and most patients appear to respond to treatment with rifampin.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11512081     DOI: 10.1086/322614

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  27 in total

Review 1.  Recommendations for treatment of human infections caused by Bartonella species.

Authors:  J M Rolain; P Brouqui; J E Koehler; C Maguina; M J Dolan; D Raoult
Journal:  Antimicrob Agents Chemother       Date:  2004-06       Impact factor: 5.191

2.  An evaluation study of enzyme-linked immunosorbent assay (ELISA) using recombinant protein Pap31 for detection of antibody against Bartonella bacilliformis infection among the Peruvian population.

Authors:  Nasikarn Angkasekwinai; Erin H Atkins; Sofia Romero; John Grieco; Chien Chung Chao; Wei Mei Ching
Journal:  Am J Trop Med Hyg       Date:  2014-02-10       Impact factor: 2.345

Review 3.  Carrion's Disease: the Sound of Silence.

Authors:  Cláudia Gomes; Joaquim Ruiz
Journal:  Clin Microbiol Rev       Date:  2017-11-29       Impact factor: 26.132

Review 4.  Emerging Infections and Pertinent Infections Related to Travel for Patients with Primary Immunodeficiencies.

Authors:  Kathleen E Sullivan; Hamid Bassiri; Ahmed A Bousfiha; Beatriz T Costa-Carvalho; Alexandra F Freeman; David Hagin; Yu L Lau; Michail S Lionakis; Ileana Moreira; Jorge A Pinto; M Isabel de Moraes-Pinto; Amit Rawat; Shereen M Reda; Saul Oswaldo Lugo Reyes; Mikko Seppänen; Mimi L K Tang
Journal:  J Clin Immunol       Date:  2017-08-07       Impact factor: 8.317

5.  Bartonella and Brucella--weapons and strategies for stealth attack.

Authors:  Houchaima Ben-Tekaya; Jean-Pierre Gorvel; Christoph Dehio
Journal:  Cold Spring Harb Perspect Med       Date:  2013-08-01       Impact factor: 6.915

Review 6.  Intruders below the radar: molecular pathogenesis of Bartonella spp.

Authors:  Alexander Harms; Christoph Dehio
Journal:  Clin Microbiol Rev       Date:  2012-01       Impact factor: 26.132

7.  Differential expression of the invasion-associated locus B (ialB) gene of Bartonella bacilliformis in response to environmental cues.

Authors:  Sherry A Coleman; Michael F Minnick
Journal:  Microb Pathog       Date:  2003-04       Impact factor: 3.738

8.  Isolation and characterization of Bartonella bacilliformis from an expatriate Ecuadorian.

Authors:  Shari L Lydy; Marina E Eremeeva; Deborah Asnis; Christopher D Paddock; William L Nicholson; David J Silverman; Gregory A Dasch
Journal:  J Clin Microbiol       Date:  2007-12-19       Impact factor: 5.948

Review 9.  Bartonella bacilliformis: a systematic review of the literature to guide the research agenda for elimination.

Authors:  Nuria Sanchez Clemente; Cesar A Ugarte-Gil; Nelson Solórzano; Ciro Maguiña; Paul Pachas; David Blazes; Robin Bailey; David Mabey; David Moore
Journal:  PLoS Negl Trop Dis       Date:  2012-10-25

10.  Rodent-associated Bartonella febrile illness, Southwestern United States.

Authors:  Jonathan Iralu; Ying Bai; Larry Crook; Bruce Tempest; Gary Simpson; Taylor Mckenzie; Frederick Koster
Journal:  Emerg Infect Dis       Date:  2006-07       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.